Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Farmaceutica Remedia's FCF Margin % or its related term are showing as below:
BSE:RMAH'
s FCF Margin % Range Over the Past 10 Years
Min: -3.06 Med: 0.55 Max: 3.91
Current: -1.21
During the past 13 years, the highest FCF Margin % of Farmaceutica Remedia was 3.91%. The lowest was -3.06%. And the median was 0.55%.
BSE:RMAH's FCF Margin % is ranked worse than 72.17% of 115
companies
in the Medical Distribution industry
Industry Median: 0.97
vs BSE:RMAH: -1.21
Farmaceutica Remedia FCF Margin % Related Terms
Farmaceutica Remedia FCF Margin % Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:RMAH vs MCK, CAH, COR: FCF Margin % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (BSE:RMAH) has a FCF Margin % of -5.33% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Farmaceutica Remedia and its competitors. According to the industry distribution chart, Farmaceutica Remedia ranks #83 out of 115 companies in the Medical Distribution industry, placing it in the top 72.2%.
Is Farmaceutica Remedia's FCF Margin % too high?
Farmaceutica Remedia's current FCF Margin % is -5.33%. Based on the distribution chart, Farmaceutica Remedia ranks #83 out of 115 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's FCF Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #83 out of 115 companies for FCF Margin %. This places Farmaceutica Remedia in the lower half of its industry. The industry median FCF Margin % is 0.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 0.97, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median FCF Margin % is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current FCF Margin % is -5.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current FCF Margin % is -5.33%. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current FCF Margin % is -5.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Fairly Valued.
Key valuation signals for BSE:RMAH:
FCF Margin %: -5.33%
GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for BSE:RMAH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
